Brief: VTV Therapeutics Announces Reinitiation Of Screening In CATT1 Phase 3 Trial
15/05/2025 19:53
May 15 (Reuters) - vTv Therapeutics Inc VTVT.O: VTV THERAPEUTICS ANNOUNCES REINITIATION OF SCREENING IN CATT1 PHASE 3 TRIAL EVALUATING POTENTIAL FIRST-IN-CLASS LIVER-SELECTIVE GLUCOKINASE ACTIVATOR CADISEGLIATIN FOR TYPE 1 DIABETES VTV THERAPEUTICS INC - TOPLINE CATT1 PHASE 3 DATA EXPECTED IN 2H 2026 VTV THERAPEUTICS INC - PROTOCOL AMENDMENT SHORTENS TRIAL DURATION TO 6 MONTHS Source text: ID:nGNX9tShQd Further company coverage: VTVT.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on vTv Therapeutics
See all newsBrief: Vtv Therapeutics Announces FDA Orphan Drug Designation For Hppd In Sickle Cell Disease
vTv Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
vTv Therapeutics Inc expected to post a loss of $1.04 a share - Earnings Preview
vTv Therapeutics Q2 net loss widens on higher trial costs
Brief: VTv Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)